Inflammation
Conditions
Interventions
A randomized, placebo-controlled, double-blind clinical trial will be conducted with 60 participants. Participants will be stratified according to body mass index into three categories: normal weight
n=20), overweight (body mass index between 25.0 and 29.9 kg/m²
n=20), and class I obesity (body mass index between 30.0 and 34.9 kg/m²
n=20). Within each body mass index category, participants will be randomly allocated in a 1:1 ratio to one of two intervention groups. The curcumin group (n=30) will receive oral curcumin at a dose of
Sponsors
Universidade Federal de Ciências da Saúde de Porto Alegre
Universidade Federal de Ciências da Saúde de Porto Alegre
Eligibility
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Individuals of both sexes; aged between 40 and 60 years; body mass index between 18.5 and 34.9 kg/m², classified as normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), or class I obesity (30.0–34.9 kg/m²); willingness to participate in the study and provision of written informed consent
Exclusion criteria
Exclusion criteria: Use of antibiotics or probiotics within the previous 30 days; current use of anti-inflammatory or immunosuppressive medications; presence of autoimmune, gastrointestinal, neurological, hepatic, renal diseases, or cancer; smoking; alcohol abuse; known allergy or hypersensitivity to curcumin; history of bariatric surgery; use of dietary supplements containing anti-inflammatory compounds within the previous 3 months; pregnancy or breastfeeding; participation in another clinical trial within the previous 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that curcumin supplementation will promote modulation of the inflammatory profile, assessed by changes in circulating concentrations of Interleukin-4, Interleukin-6, Interleukin-10, Interleukin-17, Interleukin-1, Interferon gamma, Tumor necrosis factor alpha, Toll-like receptor 4 and Nuclear factor kappa B in blood samples collected before the intervention and after four weeks of supplementation | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected that curcumin supplementation will promote changes in gut microbiota diversity and composition, assessed in fecal samples, and modulation of M1 and M2 monocyte phenotypes, assessed by flow cytometry in peripheral blood samples collected before the intervention and after four weeks of supplementation | — |
Countries
BR
Contacts
Public ContactAlessandra Peres
Universidade Federal de Ciências da Saúde de Porto Alegre
Outcome results
None listed